Company Performance - Charmacy Pharmaceutical Co., Ltd. ranked 38th among the top 100 wholesale enterprises in China based on revenue from its principal business in 2022[3]. - The company achieved a gross revenue of RMB 271.76 million in 2022, reflecting a significant increase from previous years[10]. - In 2023, the company's revenue reached RMB 292.74 million, with a gross profit margin increasing to 6.65% from 6.51% in 2022[18]. - The total operating revenue reached RMB 4,403,633, an increase from RMB 4,175,279 in 2022, representing a growth of approximately 5.5%[28]. - The total profit for 2023 was RMB 67,420, a decrease from RMB 122,054 in 2022, indicating a decline of about 44.9%[28]. - Net profit attributable to shareholders of the parent company was RMB 51,345 in 2023, down from RMB 90,472 in 2022, reflecting a decrease of approximately 43.2%[28]. - The Group's operating revenue for the year ended December 31, 2023, was RMB 4,403.63 million, an increase of 5.47% from RMB 4,175.28 million for the year ended December 31, 2022[168]. - The principal business revenue amounted to RMB 4,347,522,000, up from RMB 4,140,664,000 in the previous year, reflecting a growth of 5.0%[108]. Logistics and Distribution - The company operates a B2B e-commerce platform "Charmacy e-Medicine" for online ordering, inquiries, and payments[3]. - The logistics system includes a highly efficient delivery mechanism with multiple daily deliveries within specified radii[3]. - The company has received multiple awards for its logistics capabilities, including the Best Pharmaceutical Cold Chain Logistics Centre for five consecutive years[5]. - The company has established medium and large modern pharmaceutical distribution centers in Shantou, Guangzhou, Zhuhai, and Huizhou, equipped with advanced logistics technology to ensure quality and safety of pharmaceuticals[140]. - The company emphasizes the importance of high-quality management and operational excellence in selecting contractors for third-party logistics services[140]. - The Group's third-party pharmaceutical logistics commissioning business saw a year-on-year increase of over 36% in the number of customers and over 72% in corresponding revenue as of December 31, 2023[143]. Market Trends and Strategies - The pharmaceutical distribution market in China is expected to exceed RMB 4 trillion by 2028, with a compound growth rate of 7%[33]. - The company aims to understand market pattern changes and explore industrial chain demands as key strategies for stable growth and high-quality development[23]. - The company plans to leverage competitive advantages in the non-bidding market and enhance digital transformation to drive high-quality development in 2024[24]. - The company aims to improve service quality and create new channels in the pharmaceutical distribution industry to generate long-term value for shareholders[24]. - The company is committed to leveraging digital technology to optimize supply chain logistics and improve last-mile service capabilities[150]. - The company plans to actively seek domestic and international industrial cooperation opportunities to promote high-quality development[156]. Financial Position - The total assets increased to RMB 3,247,656 in 2023 from RMB 2,866,465 in 2022, marking a growth of about 13.3%[28]. - Total liabilities rose to RMB 2,649,849 in 2023, compared to RMB 2,271,403 in 2022, which is an increase of approximately 16.6%[28]. - The gearing ratio increased to 44.28% as of December 31, 2023, compared to 42.75% in the previous year[163]. - Cash and bank deposits increased to RMB112.93 million as of December 31, 2023, from RMB68.86 million as of December 31, 2022[172]. - The Group's net current assets were RMB193.14 million as of December 31, 2023, compared to RMB206.77 million as of December 31, 2022, with a current ratio of 1.07[172]. Governance and Management - The Board resolved on May 31, 2023, to elect Mr. Yan Jingbin as the chairman, replacing Mr. Yao, improving the governance structure[59]. - The responsibilities of the chairman and the CEO are separated to ensure effective checks and balances in governance[72]. - The Company established a nomination committee on November 26, 2015, in accordance with the corporate governance code[72]. - The Company has adopted a Director nomination policy to ensure diversity and suitability of candidates for the Board[75]. - The Audit Committee held two meetings on March 31, 2023, and August 25, 2023, to review the Group's annual results for the year ended December 31, 2023, and interim results for the six months ended June 30, 2023[82]. Employee and Gender Diversity - The board consists of three female directors and six male directors, achieving gender diversity in compliance with the listing rules[106]. - As of December 31, 2023, the company had 451 male employees and 380 female employees, with a gender ratio of 54% male and 46% female[105]. - The company is committed to maintaining and enhancing gender diversity within its workforce[105]. Regulatory Environment - The implementation of the Specification for Logistics Service of Medicinal Product (GB/T 30335-2023) on September 7, 2023, aims to standardize logistics service operations and promote the digital and intelligent transformation of logistics in the pharmaceutical industry[36]. - The New Regulations for pharmaceutical storage and transportation came into effect on July 1, 2023, enhancing the regulatory framework for logistics enterprises[120][125]. - The National Medical Products Administration released a draft guidance in October 2023 to promote the standardization of newly established pharmaceutical wholesale enterprises and third-party logistics, indicating a significant restructuring in the traditional pharmaceutical supply chain[40].
创美药业(02289) - 2023 - 年度财报